What is PROSTAMAX?
Prostamax is classified as a peptide bioregulator, a category of short synthetic peptides studied within the broader field of tissue-associated regulatory peptide research. Bioregulators of this type are typically composed of a small number of amino acid residues, giving them low molecular weight and a compact, well-defined primary structure relative to larger polypeptides and proteins. This structural simplicity is a defining feature of the class and is one reason such peptides are frequently used as reference materials in controlled laboratory investigations.
As a member of the bioregulator group, Prostamax is associated in the scientific literature with prostate-tissue research models, where short peptides of this kind are examined as tools for studying tissue-specific signaling and cellular processes in vitro. The compound is offered here solely as a characterized chemical reference standard; no physiological, therapeutic, or performance-related properties are claimed or implied, and it is not intended for diagnostic or clinical use.
The material is manufactured by solid-phase peptide synthesis and purified to a research grade suitable for analytical and cell-based experimental workflows. Each lot is presented as a lyophilized (freeze-dried) powder, a standard format for short peptides that supports accurate weighing, controlled reconstitution, and stable long-term handling in a laboratory setting.
Reconstitution & handling
Prostamax is supplied as a lyophilized powder that must be reconstituted before use in solution-phase research. The conventional approach for short hydrophilic peptides is dissolution in sterile or bacteriostatic water; for peptides with more limited aqueous solubility, a small volume of a mild co-solvent such as dilute acetic acid can assist initial dissolution before adjusting to the final working volume with the primary solvent. Solvent selection should be guided by the intended assay and the peptide's solubility profile, and only the volume needed for the immediate experiment should be prepared.
When reconstituting, the diluent should be directed gently against the inner wall of the vial rather than added forcefully onto the powder, allowing the peptide to dissolve without excessive agitation or foaming that can promote aggregation. The vial should be swirled or left to stand until a clear, particle-free solution forms; vortexing should be minimized. All handling is intended for qualified personnel using appropriate laboratory technique. This information describes reconstitution chemistry only and is not administration guidance.
Storage & stability
In its lyophilized form, Prostamax is stable for extended periods when stored sealed, protected from light and moisture, and kept frozen — typically at −20°C — with brief excursions to refrigerated or ambient temperature tolerated during weighing and handling. Once reconstituted, peptide solutions are considerably less stable and should be held refrigerated at 2–8°C for near-term use or divided into single-use aliquots and frozen to avoid repeated freeze-thaw cycles, which can degrade peptide integrity. Minimizing exposure to light, heat, and air helps preserve the characterized purity of the material throughout the research window.
How it's tested
Identity and purity of Prostamax are verified analytically prior to release. Reversed-phase high-performance liquid chromatography (HPLC) is used to quantify chromatographic purity, supporting the stated specification of ≥99%, while mass spectrometry (MS) is used to confirm the molecular identity of the peptide against its expected mass. Each lot is accompanied by a certificate of analysis (COA) documenting the analytical results for that specific batch, providing the traceable quality data researchers require for reproducible experimental work.